E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10053983 |
E.1.2 | Term | Corona virus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the effect of hydroxychloroquine (HCQ) + standard of care as compared to standard of care only on oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) ratio in adult patients hospitalized with moderate to severe Coronavirus Disease 2019 (COVID-19) |
|
E.2.2 | Secondary objectives of the trial |
Evaluate the clinical efficacy of HCQ + standard of care as compared to standard of care only in adult patients hospitalized with moderate to severe COVID-19
Evaluate the effect of HCQ + standard of care as compared to standard of care only on the virologic load in nasopharynx as assessed by quantitative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) counts in adult patients hospitalized with moderate to severe COVID-19
Evaluate the safety of HCQ + standard of care as compared to standard of care |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants must be hospitalized with illness consistent with COVID-19 pneumonia by chest imaging and/or clinical examination and with moderate to severe disease
Laboratory-confirmed SARS-CoV-2 infection
Onset of COVID-19 symptoms within 2 weeks before randomization
Women of childbearing potential must have a negative highly sensitive
pregnancy test at screening and should agree to use an acceptable
contraceptive method |
|
E.4 | Principal exclusion criteria |
Unlikely to survive for >48 hours from screening
Participants with critical disease or multi-organ failure
Any contraindication to HCQ or intolerance to HCQ
Any medical condition or concomitant therapy that may put the particpants at risk if they are treated with HCQ
Pregnant or breastfeeding women
Use of antiarrhythmic medications and medications known to prolong
QT interval or cause Torsades de Pointes (TdPs)
Participants with history of congenital or acquired long QT, arrhythmia,
family history of long QT or sudden cardiac death, or any other cardiac
condition that, by the judgement of the Investigator, would put the
patient at higher risk for QTc prolongation or sudden cardiac death
Participants with the following ECG findings at screening: QTcF >470
msec for women or >450 msec for men or heart rate <50 beats/minute
Participants with known glucose-6-phosphate dehydrogenase (G6PD)
deficiency |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Phase 2: Change in SpO2/FiO2 ratio from baseline to Day 15.
2. Phase 3 (may be reassessed after review of phase 2): Change in SpO2/FiO2 ratio from baseline to Day 15 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Phase 2 and Phase 3 (may be adapted for phase 3 based on phase 2 results): Change in SpO2/FiO2 ratio from baseline at Day 30.
2. Time to resolution of fever, defined as body temperature ≤36.6°C (axilla), or ≤37.2°C (oral), or ≤37.8°C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, whichever is sooner.
3. Percentage of patients reporting each severity rating on the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status.Score range 1-7 . Lower scale is worse.
4. Change from baseline in the 7-point ordinal scale score. The ordinal scale is an assessment of the clinical status. Score range 1-7 . Lower scale is worse.
5. Quantitative SARS-CoV-2 virus in the nasopharyngeal (NP) sample.
6. Percentage of patients with SARS-CoV-2 detectable in NP samples.
7. Number of participants with severe adverse events and adverse events leading to treatment or study discontinuation.
8. Number of particpants with serios adverse events. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Baseline to Day 30
2. Baseline to Day 30
3. Day 15 and Day 30
4. Day 15 and Day 30
5. Day 1,2,5,10, 15
6. Day 2,5,10
7. Baseline to Day 30
8. Baseline to Day 30 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 8 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 8 |